Fig. 2: DAT inhibitors do not increase dopamine release.

a Representative traces of simultaneously collected dLight (blue shades) and FSCV (orange shades) DA transients before and after application of cocaine. b Summary data showing that application of cocaine to dorsal striatal slices dose dependently increases peak DA transient peak amplitude measured with FSCV but not dLight photometry methods (n = 4). c Summary data showing that DA transient duration is increased with both methods following cocaine application (n = 4). d, e Similarly, the specific DAT inhibitor, nomifensine (1 μM) increases DA transient peak amplitude with FSCV but not dLight photometry measurements. f Nomifensine experiment: Amplitude and duration of transients measured with dLight photometry normalized to pre-drug conditions with the unmodified triangle waveform (−0.4 V to 1.2 V, n = 9). g The same normalized dlight photometry readout with nomifensine and modified triangle waveform (−0.4 V to 1.0 V, n = 4). h The normalized FSCV amplitude and duration changes with nomifensine and unmodified triangle waveform (−0.4 V to 1.2, n = 8). i The normalized FSCV amplitude and duration changes with nomifensine and modified triangle waveform (−0.4 V to 1.0 V, n = 4). j, k Cocaine does not increase DA transient peak height in DAT KO mice in photometry (j) and FSCV measurement (k). l, m Schematic diagram of the model for DAT inhibitor-induced increases in dopamine transient peak height measured using FSCV without DAT inhibitor (l) and with DAT inhbitor (m). Error bars represent the SEM. Raw data in panels (b), (c), (f), (g), (h), (i) are provided as a Source data file.